Differences in COVID-19 Vaccination and Experiences among Patients with Hypertension in Colombia and Jamaica during the COVID-19 Pandemic

Introduction

Coronavirus disease 2019 (COVID-19) was declared a public health emergency of international concern on 30 January 2020. Non-pharmaceutical interventions such as border closures, curfews, mandatory face masks, and hand sanitization were implemented in countries to stave off waves of the pandemic (1). The impact of non-pharmaceutical interventions (NPI) disrupted multiple economic sectors, social norms and individual’s livelihoods, disproportionately affecting the fragile economies of low and middle income countries (LMICs) (2). This was further exacerbated by delays in access to vaccines – resulting in a prolonged use of the NPIs for disease management in these settings which slowed economic recovery in these settings (3).

In Jamaica and Colombia, the health sector experienced direct and indirect consequences of the COVID-19 response which likely contributed to the excess deaths observed during the pandemic (4). Direct effects of the pandemic included disruption of medication supply chains and health services as non-COVID care was cancelled or delayed (5,6). Potential indirect impacts include increase in body mass index due to changes in diet and physical activity, exposure to domestic violence and an increase in mental health disorders such as depression and anxiety (7). These would have special impacts in persons living with chronic diseases such as hypertension (8–10).

Hypertension was identified as one of the risk factors for COVID-19 infection, severe COVID-19 and death (11,12). As a result, these patients were prioritized for vaccination and shielding as part of the COVID-19 response worldwide. Differences in vaccine acceptance between and within countries were recorded including variations by ethnic groups (13,14). Jamaica for instance had approximately 26.3% of the population fully vaccinated by December 31, 2022 compared to 71.1% of the population in Colombia (15). Low vaccine acceptance has also been recorded for ethnic minorities in the United States of America and the United Kingdom (14).

The COVID-19 experiences of persons residing in LMICs during the pandemic are not well documented despite the burden of non-communicable diseases (NCDs) and the propensity for sustained disruptions in health care delivery and supply chain management. As part of a needs assessment for the Caribbean and South America Team-based Strategy to Control Hypertension (CATCH) Study conducted during the pandemic, we were able to explore the COVID-19 experiences of hypertensive patients in Colombia and Jamaica and examined factors associated with vaccine acceptance. Conducting research in these two settings with significant differences in vaccination uptake also provided a unique opportunity to understand reasons for vaccine hesitancy that may be relevant to developed countries such as the USA where vaccine uptake in Black and Hispanic communities was low.

Methods

Results

Two hundred and eighty-eight people with hypertension were surveyed in each country (total of 576 participants). The majority of participants were female (68.5%), ≥ 60 years old (70.9%), employed/retired (69.7 %) and primarily from urban areas (68.1%). Colombian participants were older (mean age 66.5 vs 62.5 years old) and had higher proportion of persons with “more than high school education” (30.3% vs 17.2%, p=0.011). Higher levels of being unemployed (14.0% vs 6.0%, p<0.001) and “never married” (34.0% vs 5.5%, p<0.001) was reported in Jamaica.

Discussion

Our study found significantly higher levels of COVID-19 infection, fear of COVID-19 and COVID-19 vaccine acceptance in patients with hypertension in Colombia compared to Jamaica. Since hypertension is a risk factor for COVID-19 infection and severe COVID-19, these patients were targeted for immunization against COVID-19 across LAC (16). Colombia and Jamaica were the first countries to receive COVID-19 vaccines in the Americas and the Caribbean respectively through the COVID-19 Vaccine Global Access (COVAX) initiative (17). A meta-analysis examining vaccine acceptance in LAC reported high levels of vaccine acceptance (pooled prevalence of 78%, 95% CI: 74.0%–82.0%) but only one Caribbean country, Puerto Rico, was included in the pooled analysis (18).

In our study, COVID-19 vaccination was significantly higher in Colombia compared to Jamaica (90.6% versus 46.7%, p<0.001). These findings are similar to the differences in COVID-19 vaccine acceptance in the general population of both countries. By the end of the study period (February 1 2022), 61.2% and 22.0% of the general population in Colombia and Jamaica respectively were fully vaccinated (19,20). To date, Jamaica has the second lowest level of COVID-19 vaccination in the Caribbean with approximately 30% of the population fully vaccinated.

Low acceptance of COVID-19 vaccine in LMICs has been attributed to the global inequity in vaccine distribution and vaccine hesitancy (21). Conceptual frameworks such as the “three Cs model of vaccine hesitancy” indicate that complacency or low perceived risk of vaccine preventable diseases as well as convenience (e.g. availability and acceptability) and confidence (or trust) are the main factors that influence vaccine hesitancy (22,23). Of note, 44.4% of Jamaica’s participants were willing to be vaccinated, if available, suggesting that “convenience” or accessibility of COVID-19 vaccines may have contributed to the low uptake despite the establishment of fixed vaccination sites across the island.

Meta-analyses show that female sex, younger age, unemployment and lower educational attainment are associated with vaccine hesitancy (13,24). Our analysis did not show any associations between vaccination and age, sex, education, or location (urban/rural). However, in multivariate models, vaccination was associated with fear of COVID-19 (adjusted OR 2.71 (1.20-6.13) and fear of COVID-19 was significantly higher in Colombia compared to Jamaica (68.8 vs 6.5%). Although COVID-19 infection (self or family member) is reported as a predictor for vaccine acceptance in some studies, we did not find an association between vaccination and history of COVID-19 infection when models adjusted for socio-demographic variables and country of residence (25,26).

Understanding and targeting the reasons for complacency or low perceived threat of COVID-19 infection in LMICs such as Jamaica and among ethnic minorities in HIC should be a priority for improving vaccine acceptance. Inadequate access to diagnostic testing resulting in under-diagnosis of COVID-19 infections and deaths is one possible explanation for “complacency” in Jamaica. Many LMIC had a shortage of rapid tests due to global inequities in rapid testing and excess deaths during the pandemic have been attributed to undiagnosed COVID-19 and inadequate diagnostic capacity(27).

COVID-19 antigen rapid testing was introduced in Colombia and Jamaica in July 2020 and in September 2020 respectively (28,29). Colombia boasts having one of the highest COVID-19 testing rates in LAC with 33.9 million tests (or 666,009 tests per million people) done up to April 2022 (30,31). COVID-19 testing was widely available and by March 2022, the number of COVID-19 tests ranged from 13,000 to 39,000 per day. In Jamaica, COVID-19 testing targeted hospitalized persons as well as symptomatic persons seeking care at public health facilities. Rapid testing was available in the private sector but the high costs made home testing unaffordable for most of the population. Approximately 320,000 tests per million people were done in Jamaica by March 2022 and 14,000 rapid tests were done between January 30 and February 5, 2022 (32). This difference in access to testing in Jamaica and Colombia may also explain the finding that Colombia’s participants more commonly tested positive (24.2% vs 6.3%, p<0.001), had a family member or close friend test positive (54.5% vs, 21.6%; p<0.001) and experienced losing a family member or friend to COVID-19 (21.5% vs 7.8%, p<0.001).

Low complacency or perceived threat of COVID-19 and experiences with COVID-19 infection (self and family member testing positive) may also be due to the severity of the pandemic in each country. By February 1, 2022, Colombia which has a population of 52.1 million people was experiencing its 3^rd wave of COVID-19 with a cumulative total of 5,901,715 cases and 134,551 deaths, a crude mortality rate of 258 deaths per 100,000 people (33,34). In contrast, Jamaica has a population of 2.9 million people and recorded 124,806 cases, 2663 deaths, crude mortality rate of 92 deaths per 100,000 population (35). Jamaica was also experiencing its 3^rd wave. The dominant strain was Omicron BA1 in both countries (30). Based on the higher crude mortality rate in Colombia, it is possible that Colombia experienced more severe waves of COVID-19 with confounding by age, co-morbidities or other factors.

Although not well documented, the pandemic’s impact on health care delivery is likely to be greater in LMICs as they bear the burden of NCDs (70% NCD deaths, 85% premature deaths due to NCDs) and lack resilient health systems (6,36). Our study found that most participants (>90%) in Colombia and Jamaica did not experience reduced access to prescription medications or to a doctor in primary care due to service disruptions or curfews. Medication adherence was generally not affected by any of the COVID-19 experiences measured in our study. However, urban/rural differences were observed. For example, accessing doctors or prescription medications due to clinic or pharmacy closure was at least 5 times more common for participants in rural areas compared to urban areas. High levels of service disruption due to NPIs are reported in other studies with important impacts on hypertension care. For example, a 2020 World Health Organization (WHO) survey of 163 member states showed that 53% countries surveyed in the pandemic had disruption of services for hypertension treatment (37). Other studies reported reduced access to prescription medications and medication adherence as well as delayed diagnoses for persons with NCDs(38,39). Shah et al(40) showed that uncontrolled hypertension increased from 15% to 19% during the pandemic in the USA. A more detailed assessment of the impact of NPIs on health care delivery is needed to avoid interruption in care and adverse health outcomes for patients with hypertension and other chronic diseases.

Our study has important strengths as it provides information on COVID-19 experiences from a relatively large sample of hypertensive patients in two LAC countries. Although LMICs are disproportionately affected by NCDs such as HTN and COVID-19, few studies record vaccine acceptance and other COVID-19 experiences in these countries. Understanding the experiences of persons with hypertension during the COVID-19 pandemic will provide important information for planning the response to future shocks to the health system including epidemics like COVID-19 and Chikungunya. Studies documenting patient experiences in different LMIC settings are of particular value in understanding how local factors – including health care systems – impacted these experiences. While there is documentation of differences in vaccine uptake in minority populations in the USA there are limited data on these experiences in many of the source populations to which these ethnic groups belong. This provides additional insight into factors that influenced this practice.

However, this study has some limitations. Some documented predictors of vaccination (e.g. trust in government and source of vaccine information) and important COVID-19 experiences (e.g. use of Telehealth, access to other diagnostic and screening tests) were not captured in this study. Although we report low levels of service disruption affecting prescribed medications, the quality and nature of health services as well as subsequent health outcomes for persons with hypertension need to be assessed. Vaccine acceptance and recall of COVID-19 experiences are time-dependent and may have changed given the dynamic nature of the pandemic response. Finally, the findings may not be generalizable to other countries in LAC, but provides important information for improving vaccine acceptance in future pandemics.

Conclusion

Access to rapid testing and severity of the pandemic are possible explanations for the different experiences with COVID-19 infection, complacency and COVID-19 vaccine acceptance in Colombia and Jamaica. Low perceived threat of COVID-19 (or complacency) and inadequate access to COVID-19 vaccination (convenience) may have contributed to the significantly lower COVID-19 vaccination uptake in Jamaica compared to Colombia but did not explain the significant country differences in uptake in these setting. Ensuring equitable distribution and access to rapid testing may be important for improving vaccine uptake in future pandemics or public health emergencies. Greater emphasis should be placed on community engagement which is necessary for building trust and strengthening implementation of national responses. A comprehensive review of the COVID-19 response and experiences in LMIC can provide valuable information for public health policy and planning.

Disclosure

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. No copyrighted materials were used in this article.

Disclaimer

The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.